Depression Clinical Trials in Baltimore, MD

Depression Clinical Trials in Baltimore, MD

View the best 10 depression medical studies in Baltimore, Maryland. Access promising new therapies by applying to a Baltimore-based Depression clinical trial.

Trials in Baltimore, Maryland

Here are the top 10 medical studies for depression in Baltimore, Maryland

Image of Sante Cannabis in Montréal, Canada.

IGC-AD1

Cannabinoid

Recruiting0 awardsPhase 2
This trial tests a natural THC-based medicine called IGC-AD1, given in small doses regularly. It targets people aged 60 and above with Alzheimer's-related dementia who have been experiencing agitation. The THC in the medicine helps reduce agitation by interacting with brain signals. The most recent trial reported significant improvement in agitation using nabilone.
Image of Johns Hopkins School of Nursing in Baltimore, United States.

PRIME Intervention

Behavioral Intervention

Recruiting1 award6 criteria
This trial aims to help older women with disabilities who experience chronic pain and depression. The intervention includes home visits and virtual group sessions to help participants reduce pain and improve mood.
Image of Advanced Research Center /ID# 227073 in Anaheim, United States.

Placebo +1 More

Pharmacotherapy

Recruiting1 awardPhase 3
This trial is testing the safety and effectiveness of Cariprazine for treating depressive episodes in children and teenagers with bipolar I disorder. The goal is to find out if Cariprazine can help young people with this condition. Cariprazine is an atypical antipsychotic recently approved for the treatment of depressive episodes in adults with bipolar I disorder.
Image of Johns Hopkins Hospital / Johns Hopkins University in Baltimore, United States.

Transcranial Direct Current Stimulation

Device

Recruiting0 awards
This trial is studying whether a non-invasive brain stimulation technique can help improve non-motor symptoms in people with Parkinson's disease.
Image of National Institute on Drug Abuse in Baltimore, United States.

Arm 2: Nicotine Patch

Recruiting0 awards
This trial is testing how nicotine affects symptoms of depression and related brain function. People aged 18 to 60 who do not smoke or use nicotine products are eligible. Participants will have 3 or 4 study visits over 1 to 4 months. Each visit will include urine and breath tests, 3 MRI scans, and a blood test.
Image of University of Arizona in Tucson, United States.

Subanesthetic dose intravenous ketamine (KET) +1 More

NMDA Receptor Antagonist

Recruiting3 awardsPhase 4
This trial compares two treatments for patients with severe depression who are at risk of suicide. One treatment uses electric currents to change brain activity, while the other uses a low dose of a fast-acting drug. The goal is to find out which treatment works better for rapid relief. The drug has recently emerged as a fast-acting alternative for patients with treatment-resistant depression.
Image of Washington DC VA Medical Center, Washington, DC in Washington, United States.

Omnis Salutis

Behavioral Intervention

Recruiting1 award
This trial tests Omnis Salutis, a program for recent veterans of the Afghanistan and Iraq conflicts. The program helps veterans set and share their health goals with doctors and support systems to improve their well-being.
Image of Chicago Research Center in Chicago, United States.

Aticaprant

Recruiting1 awardPhase 3
This trial aims to see if aticaprant is effective in preventing the return of depression symptoms when added to antidepressant therapy in individuals with major depressive disorder who have already responded well to aticaprant treatment
Image of Clinical Site in Anaheim, United States.

Lumateperone

Behavioural Intervention

Recruiting1 awardPhase 3
"This trial is studying the effectiveness of a new treatment for children with bipolar disorder who are also experiencing major depressive episodes. The study is being conducted at multiple locations and will involve random assignment of participants to receive
Image of Site 4082 in Oceanside, United States.

ALTO-203

Procedure

Recruiting0 awardsPhase 2
This trial aims to study the effects of ALTO-203 in patients with Major Depressive Disorder (MDD) through two treatment periods. In the first period, participants will receive a single dose of

Phase 3 Trials

Trials With No Placebo

View More Related Trials

Frequently Asked Questions

Do I need insurance to participate in a trial?
Almost all clinical trials will cover the cost of the 'trial drug' — so no insurance is required for this. For trials where this trial drug is given alongside an already-approved medication, there may be a cost (which your insurance would normally cover).
Is there any support for travel costs?
Many of the teams running clinical trials will cover the cost of transportation to-and-from their care center.
Will I know what medication I am taking?
This depends on the specific study. If you're worried about receiving a placebo, you can actively filter out these trials using our search.
How long do clinical trials last?
Some trials will only require a single visit, while others will continue until your disease returns. It's fairly common for a trial to last somewhere between 1 and 6 months.
Do you verify all the trials on your website?
All of the trials listed on Power have been formally registered with the US Food and Drug Administration. Beyond this, some trials on Power have been formally 'verified' if the team behind the trial has completed an additional level of verification with our team.
How quickly will I hear back from a clinical trial?
Sadly, this response time can take anywhere from 6 hours to 2 weeks. We're working hard to speed up how quickly you hear back — in general, verified trials respond to patients within a few days.